Pazopanib with Telavancin Interaction Details
Brand Names Associated with Pazopanib
- Pazopanib
- Votrient®

Medical Content Editor Dr. Brian Staiger, PharmD
Last updated
Dec 20, 2023
Interaction Effect
An increased risk of QT interval prolongation
Interaction Summary
Both pazopanib and telavancin have been associated with prolonged QT interval. Therefore, caution is warranted if these agents are used concomitantly as this may result in additive QT interval prolongation and may increase the risk of cardiac adverse events, including ventricular arrhythmias and/or torsade de pointes. Monitoring of ECG and electrolytes (calcium, magnesium, and potassium) is recommended .
Severity
Major
Onset
Unspecified
Evidence
Theoretical
How To Manage Interaction
Due to the potential for additive effects on the QT interval and an increased risk of serious cardiac events, including torsade de pointes, use caution when pazopanib is used concomitantly with other drugs that prolong the QT interval, such as telavancin. Closely monitoring of ECG and electrolytes (calcium, magnesium, and potassium) is recommended .
Mechanism Of Interaction
Additive effects on QT interval prolongation
Literature Reports
A) In 3 clinical trials, QTc prolongation greater than 60 msec was observed in 1.5% (15 of 2062) of patients treated with telavancin 10 mg/kg compared with 0.6% (6 of 2062) patients treated with vancomycin. In these studies, 21% (214 of 1029) of telavancin-treated patients and 16% (164 of 1033) of vancomycin-treated patients received concomitant medications known to prolong QTc. Of the patients experiencing QTc prolongation of greater than 60 msec, 9 telavancin-treated patients and 1 vancomycin-treated patient received concomitant medications known to prolong the QTc interval, and less than 1% in each group did not receive a concomitant medication known to prolong the QTc interval. A separate analysis revealed that 1 telavancin-treated patient and 2 vancomycin-treated patients experienced a QTc greater than 500 msec. No patients experienced a cardiac adverse event attributed to QTc prolongation .
B) In a randomized, double-blind, multiple-dose, positive- and placebo-controlled, parallel study, maximum QTc prolongation of 11.6 msec (upper 90% confidence limit (CL), 16 msec) and 15.1 msec (upper 90% CL, 20 msec) was observed in patients treated with telavancin 7.5 mg/kg and 15 mg/kg, respectively, compared with 21.6 msec (upper 90% CL 26 msec) in the positive-control group. Healthy subjects (n=160) were randomized to telavancin 7.5 mg/kg, telavancin 15 mg/kg, positive control, or placebo infused over 60 minutes once daily for 3 days. At the end of the infusion, the mean maximum baseline-corrected, placebo-corrected QTc prolongation estimate for telavancin 10 mg/kg (based on interpolation of the data from patients treated with telavancin 7.5 mg/kg and 15 mg/kg) was 12 to 15 msec compared with 22 msec for the positive control. One hour after infusion, the maximum QTc prolongation for telavancin-treated patients was 6 to 9 msec compared with 15 msec for the positive control .
Pazopanib Overview
-
Pazopanib is used to treat advanced renal cell carcinoma (RCC, a type of cancer that begins in the cells of the kidneys) in adults. Pazopanib is in a class of medications called kinase inhibitors. It works by slowing or stopping the spread of cancer cells.
Return To Our Drug Interaction Homepage
Feedback, Question Or Comment About This Information?
Ask Dr. Brian Staiger, PharmD, our medical editor, directly! He's always more than happy to assist.
Definitions
Severity Categories
Contraindicated
These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.
Major
This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.
Moderate
This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.
Minor
While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.
Onset
Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.
Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.
Evidence
Level of documentation of the interaction.
Established: The interaction is documented and substantiated in peer-reviewed medical literature.
Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.
How To Manage The Interaction
Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.
It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.
Mechanism Of Interaction
The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.
Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.
Where Does Our Information Come From?
Information for our drug interactions is compiled from several drug compendia, including:
The prescribing information for each drug, as published on DailyMED, is also used.
Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.
The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.